全文获取类型
收费全文 | 1278500篇 |
免费 | 98045篇 |
国内免费 | 1989篇 |
专业分类
耳鼻咽喉 | 18423篇 |
儿科学 | 44365篇 |
妇产科学 | 35008篇 |
基础医学 | 182166篇 |
口腔科学 | 33586篇 |
临床医学 | 111246篇 |
内科学 | 258211篇 |
皮肤病学 | 28034篇 |
神经病学 | 100365篇 |
特种医学 | 51202篇 |
外国民族医学 | 660篇 |
外科学 | 196379篇 |
综合类 | 27050篇 |
现状与发展 | 1篇 |
一般理论 | 377篇 |
预防医学 | 95715篇 |
眼科学 | 27913篇 |
药学 | 94768篇 |
2篇 | |
中国医学 | 2422篇 |
肿瘤学 | 70641篇 |
出版年
2018年 | 13134篇 |
2017年 | 9965篇 |
2016年 | 10896篇 |
2015年 | 12372篇 |
2014年 | 17163篇 |
2013年 | 26211篇 |
2012年 | 36018篇 |
2011年 | 38052篇 |
2010年 | 22804篇 |
2009年 | 21807篇 |
2008年 | 36636篇 |
2007年 | 39247篇 |
2006年 | 39498篇 |
2005年 | 38437篇 |
2004年 | 37591篇 |
2003年 | 36444篇 |
2002年 | 35797篇 |
2001年 | 63987篇 |
2000年 | 66494篇 |
1999年 | 56408篇 |
1998年 | 15128篇 |
1997年 | 13755篇 |
1996年 | 14195篇 |
1995年 | 13452篇 |
1994年 | 12765篇 |
1993年 | 11790篇 |
1992年 | 44554篇 |
1991年 | 43464篇 |
1990年 | 42218篇 |
1989年 | 40112篇 |
1988年 | 36895篇 |
1987年 | 36240篇 |
1986年 | 33622篇 |
1985年 | 32280篇 |
1984年 | 24137篇 |
1983年 | 20269篇 |
1982年 | 11723篇 |
1981年 | 10691篇 |
1980年 | 9515篇 |
1979年 | 21341篇 |
1978年 | 14822篇 |
1977年 | 12535篇 |
1976年 | 11694篇 |
1975年 | 12624篇 |
1974年 | 14662篇 |
1973年 | 14117篇 |
1972年 | 12945篇 |
1971年 | 11731篇 |
1970年 | 11053篇 |
1969年 | 10026篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
31.
p53 expression and disease outcome of breast cancer patients undergoing primary chemotherapy with anthracycline-containing regimens 总被引:3,自引:0,他引:3
Primary chemotherapy administered to breast cancer patientsis the best model to identify baseline features able to predictwhich patients may be most likely to benefit or not from a cytotoxicregimen. In the March issue of Annals of Oncology two papersevaluated the predictive role of immunohistochemical p53 expressionon 相似文献
32.
33.
34.
The antiepileptic efficacy and tolerability of oxcarbazepine, used both as monotherapy and adjunctive therapy, were observed for 1 year in 202 adult patients, aged 17-83 years, with newly diagnosed or refractory partial epilepsy in clinical practice in Italy. At first observation, the seizure free rate was 72.2% in newly diagnosed patients given monotherapy, 40% in patients in whom oxcarbazepine replaced another monotherapy and 10.3% in patients given oxcarbazepine as adjunctive therapy. At least 50% reduction in seizure frequency was achieved in 90.7, 72 and 57%, respectively. Efficacy increased with the duration of treatment (p < 0.0001). In the 160 completers the seizure free rate was 61.3% with monotherapy and 28% with adjunctive therapy. 16.3% of patients reported adverse effects, mainly sedation and sleepiness; 5% discontinued oxcarbazepine because of adverse events. OXC is an effective and well-tolerated antiepileptic agent for the long-term treatment of partial epilepsy in adults. 相似文献
35.
36.
K P Sylvester S R Desai A U Wells D M Hansell M Awogbade S L Thein A Greenough 《The European respiratory journal》2006,28(4):832-838
The aim of this study was to determine whether patients with sickle cell disease (SCD) in steady state had pulmonary abnormalities seen on high-resolution computed tomography (HRCT) and whether any abnormalities correlated with contemporaneously diagnosed lung function abnormalities. A subsidiary question was whether the results of a noninvasive measure of haemolysis (end-tidal carbon monoxide (ETCO) levels) correlated with pulmonary function abnormalities. Thirty three patients with SCD, median (range) age 36 yrs (17-67 yrs) were examined. The degree of lobar volume loss and ground-glass opacification and prominence of central vessels on HRCT were quantitatively assessed. Pulmonary function was assessed by measurements of lung volumes, spirometry, gas transfer and oxygen saturation. ETCO levels were measured using an end-tidal CO monitor. Forced expiratory volume in one second (FEV1), forced vital capacity and total lung capacity significantly correlated with HRCT findings, particularly lobar volume loss. ETCO levels significantly negatively correlated with FEV1, vital capacity measured using a plethysmograph, specific airway conductance and arterial oxygen saturation measured by pulse oxymetry. In conclusion, the present results suggest that high-resolution computed tomography noninvasive assessment of haemolysis might be useful to identify sickle cell disease patients with respiratory function impairment. 相似文献
37.
R H Green C E Brightling S McKenna B Hargadon N Neale D Parker C Ruse I P Hall I D Pavord 《The European respiratory journal》2006,27(6):1144-1151
There is increasing evidence that the assessment of eosinophilic airway inflammation using induced sputum and measurement of airway hyperresponsiveness provides additional, clinically important information concerning asthma control. The aim of this study was to directly compare the effects of different treatments on these markers in patients with asthma and persistent symptoms, despite the use of low-dose inhaled corticosteroids. A double-blind four-way crossover study was performed, which compared a 1-month treatment with budesonide 400 mug b.i.d., additional formoterol, additional montelukast and placebo in 49 patients with uncontrolled asthma despite budesonide 100 mug b.i.d., with each treatment separated by a 4-week washout period. The change in sputum eosinophil count with formoterol (2.4 to 3.8% change, 0.6-fold reduction, 95% confidence interval (CI) 0.5-0.9) differed significantly from placebo (2.8 to 2.5% change, 1.1-fold reduction, 95% CI 0.7-1.6) and high-dose budesonide (2.7 to 1.6% change, 1.6-fold reduction, 95% CI 1.2-2.2). The effects of montelukast did not differ from placebo. The changes in methacholine airway responsiveness were small and did not differ between treatments. High-dose budesonide had the broadest range of beneficial effects on other outcomes, including symptom scores, morning peak expiratory flow and forced expiratory volume in one second. In conclusion, treatment given in addition to low-dose inhaled corticosteroids results in modest benefits. Formoterol and high-dose budesonide have contrasting effects on eosinophilic airway inflammation. 相似文献
38.
C T Gan G P McCann J T Marcus S A van Wolferen J W Twisk A Boonstra P E Postmus A Vonk-Noordegraaf 《The European respiratory journal》2006,28(6):1190-1194
The aim of the current study was to investigate whether alterations in N-terminal pro brain natriuretic peptide (NT-proBNP) reflect changes in right ventricular structure and function in pulmonary hypertension patients during treatment. The study consisted of 30 pulmonary hypertension patients; 15 newly diagnosed and 15 on long-term treatment. NT-proBNP, right heart catheterisation and cardiac magnetic resonance imaging measurements were performed, at baseline and follow-up. There were no significant differences between newly diagnosed patients and those on treatment at baseline or follow-up with respect to NT-proBNP, haemodynamics and right ventricular parameters. Relative changes in NT-proBNP during treatment were correlated to the relative changes in right ventricular end-diastolic volume index (r = 0.59), right ventricular mass index (r = 0.62) and right ventricular ejection fraction (r = -0.81). N-terminal pro brain natriuretic peptide measurements reflect changes in magnetic resonance imaging-measured right ventricular structure and function in pulmonary hypertension patients. An increase in N-terminal pro brain natriuretic peptide over time reflects right ventricular dilatation concomitant to hypertrophy and deterioration of systolic function. 相似文献
39.
40.
C. M. Crceles J. M. Serrano P. Marín E. Escudero E. Fernndez‐Varn 《Transboundary and Emerging Diseases》2006,53(6):300-304
The pharmacokinetics (PK) of moxifloxacin in healthy white New Zealand rabbits was studied following intravenous (IV) and subcutaneous (SC) administration routes as well as a SC long‐acting poloxamer 407 gel formulation (SC‐P407). Moxifloxacin concentrations were determined by high‐performance liquid chromatography assay with fluorescence detection. Mean half‐life for IV, SC and SC‐P407 routes was 2.15, 5.41 and 11.09 h. Clearance value after IV dosing was 0.78 l/kg/h. After SC administration, the mean absolute bioavailability was 117% and the Cmax was 1.61 ± 0.49 mg/l. After SC‐P407 administration, the bioavailability was 44% and the Cmax 1.83 was ±0.62 mg/l. No adverse effects were observed in any of the rabbits following IV, SC and SC‐P407 administration of moxifloxacin. Minimal inhibitory concentrations of moxifloxacin against different strains of Staphylococcus aureus from different european countries were used to compute the main pharmacodynamic (PD) surrogate markers of efficacy. The high tolerability of this SC‐P407 formulation and the favourable PK behaviour such as the long half‐life, acceptable bioavailability and excellent PK–PD ratios achieved indicate that it is likely to be effective in rabbits. 相似文献